A method of treating pneumonia in a patient is disclosed comprising administering an effective amount of an IL-6 antagonist to a patient identified as having elevated ferritin level. Also disclosed is a method of achieving an improved clinical response in a patient with pneumonia comprising: a. measuring ferritin level in the patient, and b. administering an effective amount of an IL-6 antagonist to the patient identified as having an elevated ferritin level. The improved clinical response achieved includes: no death by Day 28, not mechanically ventilated by Day 28 (wherein the patient was not mechanically ventilated at baseline), better ordinal score at Day 28, and/or reduced time to hospital discharge within 28 days, compared to the clinical response in a patient with pneumonia and ferritin level that is not elevated. Moreover, a method of reducing time to hospital discharge in a patient with pneumonia comprising administering an effective amount of the IL-6 antagonist to the patient is disclosed, wherein the patient prior to treatment: a. is receiving non-invasive ventilation or high flow oxygen, or is intubated and being mechanically ventilated, and b. has been identified as having elevated IL-6 level.

Methods, systems and kits for the early diagnosis or prediction of systemic inflammatory response syndrome (SIRS) including sepsis in asymptomatic patients, such as patients undergoing a surgical intervention, are provided. Some embodiments include a method and system for the detection or diagnosis of SIRS, or detection or diagnosis of a risk to suffer from or develop SIRS, in an asymptomatic patient comprising the steps of determining the level of IL-6 (or a variant thereof) in a sample from the patient; comparing the level of IL-6 (or a variant thereof) to a reference level; detecting or diagnosing SIRS or diagnosing a risk to suffer from or develop SIRS, wherein the sample is isolated at least 2 times at short intervals and the determining and comparing steps are both repeated for each sample. Also provided are methods, systems and kits for therapy monitoring and mortality prediction.

The invention relates to method of diagnosis a subject suffering from Adult-onset Still's disease and further to determine the disease course of the subject suffering from Adult-onset Still's disease.

The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

The disclosure relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23, but do not inhibit IL-12. The disclosure also relates to methods of selecting a subject amenable to IL-23 inhibition therapy to treat Crohn's disease as well as methods of identifying a patient sub-population amenable to such treatment.

The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.

The present disclosure relates to a composition capable of diagnosing cancer, specifically pancreatic cancer or the like, a diagnostic kit comprising the same, and a method of providing information for diagnosis using the composition. Also, the present disclosure relates to a pharmaceutical composition capable of preventing or treating pancreatic cancer.

A biosensor for monitoring surface binding events is disclosed. The biosensor comprises an array of nanoparticles and an analyte responsive polymer. The array of nanoparticles includes a plurality of nanoparticles distributed across the nanoparticle array. The analyte responsive polymer includes a recognition element at a first end of the polymer and a terminus at a second end of the polymer distal from the recognition element, the terminus end being conjugated to the nanoparticles in the array. When the recognition element reacts with an analyte, the analyte responsive polymer creates an electrochemical signal at the surface of the nanoparticle array which can be measured to monitor surface events of the analyte responsive polymer.

Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.